Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, India.
Sinhgad College of Pharmacy, Pune, India.
Immunopharmacol Immunotoxicol. 2020 Apr;42(2):128-137. doi: 10.1080/08923973.2020.1728541. Epub 2020 Feb 18.
Asthma is a very common airway inflammatory disease for which the existing drug therapy options are insufficient. In this study, we explored the mechanisms underlying the anti-inflammatory potential of Sarsapogenin (SG) and its combination with Fluticasone (FC) in ovalbumin (OVA)-induced allergic asthma in mice. In a standard experimental model, asthma in mice was sensitized and challenged by OVA. The mice were treated with SG and SG + FC during OVA challenge. At the completion, lung weight, inflammatory cell count in bronchoalveolar lavage fluid (BALF), serum cytokines levels, immunoglobulin E (IgE) levels, lung nitrate/nitrite (NO) levels, and lung tissue oxidative stress biomarkers were determined. Histopathological evaluation of the lung tissue was also performed. Treatment of mice with SG and SG + FC combination intensely diminished the trafficking of total and differential inflammatory cells count into BALF. SG and SG + FC administration significantly reduced the production of inflammatory cytokines, serum IgE levels and restoration of antioxidant stress markers. Histopathological analysis of lung samples effectually weakened bronchial inflammation and mucus production in the lung with a significant reduction in inflammation and mucus score. Our study results suggested that SG and SG + FC effectively reduced allergic airway inflammation inhibiting pro-inflammatory cytokines, NO expressions and oxidative stress parameters. So, it could be used as a therapeutic potential agent for the treatment of asthma by decreasing its dose in combination with FC to avoid the chronic adverse effects of FC.
哮喘是一种非常常见的气道炎症性疾病，现有药物治疗选择不足。在这项研究中，我们探讨了薯蓣皂甙元（SG）及其与氟替卡松（FC）联合治疗卵清蛋白（OVA）诱导的过敏性哮喘小鼠的抗炎潜力的机制。在标准实验模型中，通过 OVA 致敏和激发来诱导哮喘。在 OVA 激发期间，用 SG 和 SG+FC 对小鼠进行治疗。完成后，测定肺重、支气管肺泡灌洗液（BALF）中炎性细胞计数、血清细胞因子水平、免疫球蛋白 E（IgE）水平、肺硝酸盐/亚硝酸盐（NO）水平和肺组织氧化应激生物标志物。还对肺组织进行了组织病理学评估。用 SG 和 SG+FC 联合治疗可强烈减少总炎性细胞和差异炎性细胞计数进入 BALF 的转运。SG 和 SG+FC 给药可显著降低炎症细胞因子、血清 IgE 水平的产生，并恢复抗氧化应激标志物。对肺样本的组织病理学分析有效地减弱了支气管炎症和肺内粘液的产生，炎症和粘液评分显著降低。我们的研究结果表明，SG 和 SG+FC 通过抑制促炎细胞因子、NO 表达和氧化应激参数，有效减轻过敏性气道炎症。因此，它可以作为一种治疗哮喘的潜在药物，与 FC 联合使用以减少其剂量，避免 FC 的慢性不良反应。
